ALLO - CIK 0001737287
The table below shows Allogene Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$149.25M | -$200.30M | -$237.73M | -$220.52M | -$184.81M | -$115.09M |
| Capital expenditure | $386.00K | $694.00K | $1.52M | $5.19M | $21.45M | $65.96M |
| Investing cash flow | $95.56M | $75.69M | $163.29M | $106.16M | $163.66M | -$505.12M |
| Dividends paid | - | - | - | - | - |
Allogene Therapeutics, Inc. reported operating cash flow of -$149.25M for fiscal year 2025. That is up 25.5% from -$200.30M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$44.65M (FY 2018) to -$149.25M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $30.16M | $116.67M | $95.69M | $2.95M | $11.96M | $633.59M |